IDEX Corporation

The filings describe a diversified industrial company whose reported growth is real but whose earnings quality depends on several specific items. Annual revenue rose from $3.27 billion in 2024 to $3.46 billion in 2025, roughly 6%, after being flat from 2023 to 2024 at $3.27 billion. The first-quarter 2026 10-Q attributes the 9% net sales increase to organic growth of 5%, favorable foreign currency, and contributions from the Micro-LAM, Inc. acquisition completed in July 2025. Management credits the Health & Science Technologies segment, with AI-driven demand for data center power and semiconductor markets and space and defense strength, for the volume gain, yet the same segment reported lower volumes in its life sciences businesses. The Fluid & Metering Technologies segment grew only 4%, and the Fire & Safety/Diversified Products segment grew 2%, with lower volumes in its Dispensing businesses. Gross margin declined to 44.9% from 45.3%, which the filing ties to price/cost pressure and unfavorable mix. Reported diluted EPS rose 28% to $1.61, while adjusted EPS rose 14% to $2.00; the reconciliation under Non-GAAP Disclosures is where readers may want to look to see which items drive that gap. The risk factors name acquisition integration, competition including rivals' use of AI, raw material and component supply, and cybersecurity as material risks. Management describes tariff effects so far as not material, while noting it will continue to monitor refunds. Read together, the documents show improving operating income alongside a margin profile that management itself describes as pressured.

Catalyst.According to the first-quarter 2026 MD&A, net sales of $886.9 million rose 9% from $814.3 million, with organic sales up 5%. Management attributes the growth primarily to higher volumes in the Health & Science Technologies segment, where net sales reached $398.4 million, up 17%. The filing cites AI-driven demand for data center power and semiconductor markets, plus strength in space and defense. Positive price across segments and net operational productivity gains also supported results, and operating income rose 21% to $172.4 million. Capital returns in the quarter included $76.3 million of share repurchases and $52.8 million of dividends.

Hidden risk.The most easily missed tension is between headline growth and margins. Gross margin fell to 44.9% from 45.3% even as sales grew, and the filing attributes the pressure to price/cost and unfavorable mix. Growth also leans on acquisitions: the risk factors state that prior acquisitions have resulted in substantial additional indebtedness and that integration may not succeed, and the HST segment's organic and acquisition components both contributed to its 17% growth. Restructuring costs fell from $17.5 million to $7.4 million, which helped reported earnings, though the quarter still includes a $4.8 million impairment in the FMT segment. Reported diluted EPS of $1.61 also sits well below adjusted EPS of $2.00, a gap readers may want to look at in the Non-GAAP Disclosures section.